Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Oligoprogressive 1

Interventions

pembrolizumab 303Carboplatin 232Cisplatin 161Paclitaxel 154Gemcitabine 153Pemetrexed 123Bevacizumab 121Docetaxel 106durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 53Lenalidomide 51venetoclax 47Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × DEAE-Dextran × 90 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡